---
$id: https://graph.org.ai/products/commodity/51111655
$type: Product
source: UNSPSC
code: "51111655"
title: "Rubitecan"
class: "51111600"
classTitle: "Antimetabolites"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Rubitecan

**UNSPSC Code**: 51111655
**Class**: [Antimetabolites](Antimetabolites.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a camptothecin analogue with the molecular formula C20H15N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H19C446XXB, chemically known as 4-ethyl-4-hydroxy-9-nitro-1h-pyrano(3,4:6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione but generally known as rubitecan, which bears US NIH Compound Identifier 123613. European Medicines Agency schedules Rubitecan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33089. The term RUBITECAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). Most nations schedule rubitecan under HS 29399900 and SITC 54149. As of Q4 2014, RUBITECAN remains the US FDA Preferred Term for this commodity. Rubitecan bears US NLM identifiers UMLS ID C0213800 and NCI Concept Code C1485. SMILES: O1CC2C(C(O)(CC)C1=O)CC1N(CC3C1NC1C(C3)C([N](=O)O)CCC1)C2=O.

